August 2023 in “European journal of dermatology/EJD. European journal of dermatology” Combining topical delgocitinib with a 308-nm excimer laser can effectively treat severe alopecia areata and vitiligo.
5 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology”
2 citations
,
November 2023 in “Acta dermato-venereologica” Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Finasteride may help treat childhood brain tumors by activating certain genes.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
January 2024 in “Journal of Clinical Images and Medical Case Reports” Baricitinib may help treat frontal fibrosing alopecia and facial papules.
10 citations
,
September 2024 in “Life” Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
August 2022 in “Dermatologic Therapy”
17 citations
,
June 2020 in “British Journal of Dermatology” Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.
16 citations
,
January 2001 in “Clinical and Experimental Dermatology” Photodynamic therapy was effective in treating multiple scalp basal cell carcinomas with minimal side effects and good cosmetic results.
February 2026 in “Annals of Case Reports” Tofacitinib helped a patient regrow hair after 40 years of total hair loss.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
4 citations
,
October 2018 in “JAMA Dermatology” Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.